KMT2C and breast cancer: Furthermore, alterations (deletions or truncating mutations that are somewhat frequent in BC patients) in the histone H3K4 methyl-transferase KMT2C (also known as MLL3) in ER+ MBC patients who received AIs were associated with poorer PFS when compared with KMT2C WT ER+ MBC patients [38].